Select Page

BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). ALX’s addition to the NBI will become effective prior to market open on Monday, December 21, 2020.